Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724815 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
A Phase 3 study, sponsored by NuPathe.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT00724815 is a Phase 3 study that has completed, run by NuPathe. The registered enrollment target is 530 participants.
The verdict
NCT00724815, a Phase 3 study, has completed, sponsored by NuPathe.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation. Key secondary objectives included: 1. The proportion of subjects who were nausea free at two hours after patch activation. 2. The proportion of subjects who were photophobia free at two hours after patch activation. 3. The proportion of subjects who were phonophobia free at two hours after patch activation.
Interventions
- DRUG Placebo
- DRUG NP101 - Sumatriptan iontophoretic transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724815
The ClinicalTrials.gov registry entry for NCT00724815 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuPathe, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00724815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724815 about?
NCT00724815 is a clinical study titled "The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine". This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours a...
What is the current status of trial NCT00724815?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2009-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00724815?
The interventions under investigation include: Placebo (DRUG), NP101 - Sumatriptan iontophoretic transdermal patch (DRUG).
Who is sponsoring clinical trial NCT00724815?
This trial is sponsored by NuPathe, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.